Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis
Our results highlight that a subgroup of carcinosarcomas patients exhibits a durable benefit from chemotherapy in the relapse settings, and suggest the use of PFS1, as a proxy of platinum-sensitivity, to select patients who might derive higher clinical benefit of a 2nd line of chemotherapy.
Authors
- Amel Kime (ORCID: https://orcid.org/0000-0001-6754-9661)
- Guillaume Beinse (ORCID: https://orcid.org/0000-0003-2731-6462)
- Sixtine De Percin (ORCID: https://orcid.org/0000-0001-5773-0205)
- Bruno Borghese (ORCID: https://orcid.org/0000-0002-6385-5829)
- Antoine Gaudet-Chardonnet
- Jérôme Alexandre (ORCID: https://orcid.org/0000-0001-5252-5800)
- Jean‐Philippe Berthet
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut Cochin (FR)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3802/jgo.2025.36.e64
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00